QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.
   Google Scholar
• Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent–report of health care provider–diagnosed and medicated attention–deficit/hyperactivity disorder: united States, 2003–2011. J Am Acad Child Adolesc Psychiatry. 2014;53(1):34–46 e2.
   PubMed Web of Science ®Google Scholar
• Swanson JM, Arnold LE, Molina BSG, et al. Young adult outcomes in the follow–up of the multimodal treatment study of attention–deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry. 2017;58(6):663–678.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–165.
   PubMed Web of Science ®Google Scholar
• Katzman MA, Bilkey TS, Chokka PR, et al. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017;17(1):302.
   PubMed Web of Science ®Google Scholar
• Cadman T, Findon J, Eklund H, et al. Six-year follow-up study of combined type ADHD from childhood to young adulthood: predictors of functional impairment and comorbid symptoms. Eur Psychiatry. 2016;35:47–54.
   PubMed Web of Science ®Google Scholar
• Meinzer MC, Pettit JW, Waxmonsky JG, et al. Does childhood attention-deficit/Hyperactivity disorder (ADHD) predict levels of depressive symptoms during emerging adulthood? J Abnorm Child Psychol. 2016;44(4):787–797.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157(5):816–818.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez I, Sanchez-Mora C, Soler Artigas M, et al. Gene-wide association study reveals RNF122 ubiquitin ligase as a novel susceptibility gene for attention deficit hyperactivity disorder. Sci Rep. 2017;7(1):5407.
   PubMedGoogle Scholar
• Sengupta SM, Smith AK, Grizenko N, et al. Locus-specific DNA methylation changes and phenotypic variability in children with attention-deficit hyperactivity disorder. Psychiatry Res. 2017;256:298–304.
   PubMed Web of Science ®Google Scholar
• Kappel DB, Schuch JB, Rovaris DL, et al. Further replication of the synergistic interaction between LPHN3 and the NTAD gene cluster on ADHD and its clinical course throughout adulthood. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):120–127.
   PubMedGoogle Scholar
• Elia J, Glessner JT, Wang K, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2011;44(1):78–84.
   PubMed Web of Science ®Google Scholar
• Gehricke JG, Kruggel F, Thampipop T, et al. The brain anatomy of attention-deficit/hyperactivity disorder in young adults - a magnetic resonance imaging study. PLoS One. 2017;12(4):e0175433.
   PubMed Web of Science ®Google Scholar
• Norman LJ, Carlisi CO, Christakou A, et al. Shared and disorder-specific task-positive and default mode network dysfunctions during sustained attention in paediatric Attention-Deficit/Hyperactivity Disorder and obsessive/compulsive disorder. Neuroimage Clin. 2017;15:181–193.
   PubMed Web of Science ®Google Scholar
• Kumar U, Arya A, Agarwal V. Neural alterations in ADHD children as indicated by voxel-based cortical thickness and morphometry analysis. Brain Dev. 2017;39(5):403–410.
   PubMed Web of Science ®Google Scholar
• Wolfers T, Arenas AL, Onnink AMH, et al. Refinement by integration: aggregated effects of multimodal imaging markers on adult ADHD. J Psychiatry Neurosci. 2017;42(6):160240.
   Web of Science ®Google Scholar
• Brennan AR, Arnsten AF. Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann N Y Acad Sci. 2008;1129:236–245.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Brown A, Seidman LJ, et al. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. J Clin Psychiatry. 2013;74(9):902–917.
   PubMed Web of Science ®Google Scholar
• Bledsoe J, Semrud-Clikeman M, Pliszka SR. A magnetic resonance imaging study of the cerebellar vermis in chronically treated and treatment-naive children with attention-deficit/hyperactivity disorder combined type. Biol Psychiatry. 2009;65(7):620–624.
   PubMed Web of Science ®Google Scholar
• Pretus C, Ramos-Quiroga JA, Richarte V, et al. Time and psychostimulants: opposing long-term structural effects in the adult ADHD brain. A longitudinal MR study. Eur Neuropsychopharmacol. 2017;27(12):1238–1247.
   PubMed Web of Science ®Google Scholar
• Subcommittee on Attention-Deficit/Hyperactivity D, Steering Committee on Quality I, Management, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–1022.
   PubMed Web of Science ®Google Scholar
• Childress AC, Berry SA. Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents. Drugs. 2012;72(3):309–325.
   PubMed Web of Science ®Google Scholar
• Mattingly GW, Wilson J, Rostain AL. A clinician’s guide to ADHD treatment options. Postgrad Med. 2017;129(7):657–666.
   PubMed Web of Science ®Google Scholar
• Pliszka S, Issues A. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.
   PubMed Web of Science ®Google Scholar
• Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–1022.
   PubMed Web of Science ®Google Scholar
• Childress AC, Sallee FR. Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder. Drugs Today (Barc). 2012;48(3):207–217.
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Wang M. Targeting prefrontal cortical systems for drug development: potential therapies for cognitive disorders. Annu Rev Pharmacol Toxicol. 2016;56:339–360.
   PubMed Web of Science ®Google Scholar
• Kozarewicz P. Regulatory perspectives on acceptability testing of dosage forms in children. Int J Pharm. 2014;469(2):245–248.
   PubMed Web of Science ®Google Scholar
• Polaha J, Dalton WT 3rd, Lancaster BM. Parental report of medication acceptance among youth: implications for everyday practice. South Med J. 2008;101(11):1106–1112.
   PubMed Web of Science ®Google Scholar
• CONCERTA® (methylphenidate HCl) Extended-Release Tablets,CII. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2018 Sep 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf.
   Google Scholar
• ADDERALL XR® (mixed salts of a single-entity amphetamine product) dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, amphetamine sulfate capsules, CII. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2018 Jun 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021303s032lbl.pdf
   Google Scholar
• Once Daily Metadate CD® (methylphenidate HCl, USP) Extended-Release Capsules 2010. [cited 2018 Jun 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021259s030lbl.pdf
   Google Scholar
• FOCALIN XR® (dexmethylphenidate hydrochloride) Extended-Release Capsules CII for oral use. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2018 Jun 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf.
   Google Scholar
• Aptensio XR^TM (methylphenidate hydrochloride extended-release) Capsules for oral use, CII. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2018 Jun 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205831s003lbl.pdf
   Google Scholar
• Ritalin LA® (methylphenidate hydrochloride) extended-release capsules. [cited 2018 Jun 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021284s034lbl.pdf
   Google Scholar
• Vyvanse® (lisdexamfetamine dimesylate) capsules for oral use. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2018 Jun 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021977s039lbl.pdf
   Google Scholar
• Chewable Tablets: A Comprehensive Review.
   Google Scholar
• Global ADHD Therapeutics Market to Reach US$ 25 Bn by 2024 – Persistence Market Research. [cited 2018 Jun 24]. Available from: https://www.prnewswire.com/news-releases/global-adhd-therapeutics-market-to-reach-us-25-bn-by-2024—persistence-market-research-590889221.html
   Google Scholar
• ClinCalc DrugStats Database. The Top 200 Drugs of 2017. [cited 2018 Jun 24]; Available from: http://clincalc.com/DrugStats/
   Google Scholar
• Quillichew ER. [cited 2018 Oct 7]. Available from: https://www.goodrx.com/quillichew-er?drug-name=quillichew+er
   Google Scholar
• QUILLICHEW ER™ (methylphenidate hydrochloride) extended-release chewable tablets, for oral use, CII. [cited 2018 Jun 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207960s005lbl.pdf
   Google Scholar
• Methylphenidate extended release chewable tablet. [cited 2018 Jun 24]. Available from: https://www.google.com/patents/WO2014028610A1?cl=en
   Google Scholar
• Abbas R, Palumbo D, Walters F, et al. Single-dose pharmacokinetic properties and relative bioavailability of a novel methylphenidate extended-release chewable tablet compared with immediate-release methylphenidate chewable tablet. Clin Ther. 2016;38(5):1151–1157.
   PubMed Web of Science ®Google Scholar
• Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277.
   PubMed Web of Science ®Google Scholar
• Abbas R, Childress AC, Nagraj P, et al. Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole. Clin Ther 2018;40(5):733–740.
   Google Scholar
• Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(8):690–699.
   PubMed Web of Science ®Google Scholar
• Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980–988.
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical global impressions. In: ECDEU assessment manual for psychopharmacology revised. Rockville: US Department of Health. 1976. p. 217–222.
   Google Scholar
• Wigal SB, Childress A, Berry SA, et al. Optimization of methylphenidate extended-release chewable tablet dose in children with ADHD: open-label dose optimization in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2018 Jun;28(5):314–321.
   Web of Science ®Google Scholar
• Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34(1):47–53.
   PubMedGoogle Scholar
• Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord. 2006;10(1):92–111.
   PubMedGoogle Scholar
• Orally effective methylphenidate extended release powder and aqueous suspension product US 8287903 B2. [cited 2018 Jun 24]. Available from: https://www.google.com/patents/US8287903
   Google Scholar
• QUILLIVANT™ XR (methylphenidate hydrochloride) for extended-release oral suspension. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2017 Mar 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202100s006lbl.pdf
   Google Scholar
• Wigal SB, Childress AC, Belden HW, et al. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2013;23(1):3–10.
   PubMed Web of Science ®Google Scholar
• Guidance for Industry Orally Disintegrating Tablets. [cited 2018 Jun 24]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070578.pdf.
   Google Scholar
• Quality Attribute Considerations for Chewable Tablets Guidance for Industry. [cited 2018 Jun 24]. Available from: http://www.gmp-compliance.org/guidemgr/files/UCM507098.PDF
   Google Scholar
• Compositions comprising methylphenidate complexed with ion-exchange resin particles. [cited 2018 Jun 24]. Available from: http://www.google.com/patents/US9089496.
   Google Scholar
• Neos Therapeutics Proprietary Technology. [cited 2018 Jun 24]. Available from: http://www.neostx.com/proprietary-pharmaceutical-technologies
   Google Scholar
• Childress AC, Kollins SH, Cutler AJ, et al. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6-12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017;27(1):66–74.
   PubMed Web of Science ®Google Scholar
• Lopez FL, Bowles A, Gul MO, et al. Effect of formulation variables on oral grittiness and preferences of multiparticulate formulations in adult volunteers. Eur J Pharm Sci. 2016;92:156–162.
   PubMed Web of Science ®Google Scholar
• Baguley D, Lim E, Bevan A, et al. Prescribing for children - taste and palatability affect adherence to antibiotics: a review. Arch Dis Child. 2012;97(3):293–297.
   PubMed Web of Science ®Google Scholar
• COTEMPLA XR-ODT (methylphenidate extended-release orally disintegrating tablets), CII. [cited 2018 Jun 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205489s000lbl.pdf
   Google Scholar
• Liu F, Ranmal S, Batchelor HK, et al. Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations. Drugs. 2014;74(16):1871–1889.
   PubMed Web of Science ®Google Scholar
• Buck M. Alternative forms of oral drug delivery for pediatric patients. Pediatr Pharmacother. A Monthly Newsletter for Health Care Professionals from the Univeristy of Virginia Children’s Hospital. 2013;19:3.
   Google Scholar
• Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav. 2001;68(3):611–627.
   PubMed Web of Science ®Google Scholar
• DAYTRANA® (methylphenidate transdermal system). HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2018 Jun 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021514s025lbl.pdf
   Google Scholar
• Cheng C, La Grenade L, Diak IL, et al. Chemical leukoderma associated with methylphenidate transdermal system: data from the US food and drug administration adverse event reporting system. J Pediatr. 2017;180:241–246.
   PubMed Web of Science ®Google Scholar
• Edwards A, Qi S, Liu F, et al. Rationalising polymer selection for supersaturated film forming systems produced by an aerosol spray for the transdermal delivery of methylphenidate. Eur J Pharm Biopharm. 2017;114:164–174.
   PubMed Web of Science ®Google Scholar
• DYANAVEL XR (amphetamine) extended-release oral suspension, CII. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2018 Jun 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208147s000lbl.pdf
   Google Scholar
• ADZENYS XR-ODT (amphetamine extended-release orally disintegrating tablets), CII. [cited 2018 Jun 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204326s002lbl.pdf
   Google Scholar
• ADZENYS ER (amphetamine) extended-release oral suspension, CII. [cited 2018 Jun 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204325s000lbl.pdf
   Google Scholar
• Wigal SB, Wigal T, Childress A, et al. The time course of effect of multilayer-release methylphenidate hydrochloride capsules: a randomized, double-blind study of adults with ADHD in a simulated adult workplace environment. J Atten Disord. 2016. 1087054716672335. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• New Treatment Option For Adults With ADHD: FOQUEST™ (Methylphenidate Controlled Release Capsules) Now Available In Canada. [cited 2018 Jun 23]. Available from: http://purdue.ca/en/2018/02/01/new-treament-option-for-adults-with-adhd-foquest-methylphenidate-controlled-release-capsules-now-available-in-canada/
   Google Scholar
• Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(6):474–482.
   PubMed Web of Science ®Google Scholar
• Ironshore Pharmaceuticals Announces Positive HLD100 Results From Open-Label Tolerability Study In Pediatric ADHD Patients http://www.ironshorepharma.com/pdf/Ironshore-Announces-Progession-of-HLD100-Into-Pivotal-Studies.pdf. [cited 2018 Jun 23]. Available from: http://www.ironshorepharma.com/pdf/Ironshore-Announces-Progession-of-HLD100-Into-Pivotal-Studies.pdf
   Google Scholar
• KP415. [cited 2018 Jun 23]. Available from: http://kempharm.com/pipeline-products/#kp415
   Google Scholar
• KP484. [cited 2018 Jun 23]. Available from: http://kempharm.com/pipeline-products/#kp484
   Google Scholar
• Rubin J, Siner D, Baker D. ADAIR: an abuse deterrent oral formulation of immedicate release dextro-amphetamine sulfate (d-amphetamine). Presented at: APSARD 2018 Annual Meeting; 2018 Jan 12-14; Washington (DC).
   Google Scholar
• ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan. [cited 2018 Jun 23]. Available from: https://www.prnewswire.com/news-releases/oradur-methylphenidate-er-capsule-achieves-primary-endpoint-in-phase-3-study-in-adhd-in-taiwan-300500866.htm
   Google Scholar